Skip to main content
Oncotarget logoLink to Oncotarget
. 2017 Sep 5;8(37):62816. doi: 10.18632/oncotarget.20631

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences

Vincenzo Quagliariello 1,2,3,16, Sabrina Rossetti 1,2, Carla Cavaliere 1,4, Rossella Di Palo 1,5, Elvira Lamantia 1,6, Luigi Castaldo 1,7, Flavia Nocerino 8, Gianluca Ametrano 1,5, Francesca Cappuccio 1,9, Gabriella Malzone 1,6, Micaela Montanari 1,10, Daniela Vanacore 1, Francesco Jacopo Romano 1, Raffaele Piscitelli 1,11, Gelsomina Iovane 2, Maria Filomena Pepe 1,6, Massimiliano Berretta 12,16, Carmine D’Aniello 1,13, Sisto Perdonà 7, Paolo Muto 5, Gerardo Botti 6, Gennaro Ciliberto 14,17, Bianca Maria Veneziani 10, Francesco De Falco 9, Piera Maiolino 11, Michele Caraglia 15, Maurizio Montella 8, Rosario Vincenzo Iaffaioli 3,16, Gaetano Facchini 1,2,16
PMCID: PMC5617551  PMID: 28977991

This article has been corrected: The institutional affiliation information for Dr. Gennaro Ciliberto was updated to include affiliation #17.

The authors sincerely apologize for this oversight.

Original article: Oncotarget. 2017; 8:30606-30616. https://doi.org/10.18632/oncotarget.16725


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES